Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Symphogen and Open Monoclonal Technology Announce Collaboration

Published: Tuesday, October 15, 2013
Last Updated: Tuesday, October 15, 2013
Bookmark and Share
Symphogen to employ OmniRat™ and OmniMouse™ transgenic platforms in product discovery.

Symphogen A/S and Open Monoclonal Technology, Inc. (OMT) have announced an alliance that provides Symphogen with unlimited access to OMT’s OmniRat® and OmniMouse® platforms.

Symphogen will use its proprietary B cell-based antibody identification technology, Symplex™, and access the diverse immune repertoires generated in OMT’s transgenic animals to develop novel human therapeutic candidates.

“OMT’s complementary transgenic animals for generation of fully human antibodies fit well with our long-standing strategy of using wild type mice and chickens and even humans as sources of rare, highly diverse antibodies,” said Ivan Horak, Chief Scientific & Medical Officer at Symphogen.

“With the success of our antibody mixture approach our need for high quality antibodies has expanded and OMT’s transgenic animals will enable us to more rapidly create new multi-antibody product candidates,” said Horak.

Dr. Roland Buelow, founder and CEO of OMT, continued, “Symphogen has demonstrated the therapeutic value of antibody cocktail approaches and the need for antibody diversity that targets unique epitopes. OmniRat is well proven, published and partnered. OmniMouse provides additional epitope coverage and the combined platforms will enable Symphogen to establish superior antibody cocktail products. This unlimited access, multi-platform partnership illustrates how OMT also adds value to rapidly growing, mid-size companies, which is an important element in OMT’s pursuit to make OmniRat and OmniMouse preferred brands in human therapeutic antibody discovery.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Symphogen to Report Preliminary Safety Data from a Phase 1 Study of Sym004
Data will be presented at the upcoming 2014 ASCO Annual Meeting in Chicago.
Friday, May 30, 2014
Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 Million
Novo A/S and PKA led the expansion with investments of €20 million each, while Danica Pension participated with its pre-financing ownership share of the additional financing.
Friday, May 03, 2013
Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH
Phase 2 data demonstrate that rozrolimupab induce a rapid increase in blood platelets of ITP patients.
Tuesday, December 13, 2011
Symphogen’s Success Attracts USD 25 Million Investment
The financing will be used to carry out clinical trials of Symphogen’s first product, anti-RhD.
Thursday, January 12, 2006
Symphogen Launches New Website and Marketing Materials
New website is accompanied by several new factsheets detailing the company, technology and products.
Wednesday, December 21, 2005
Scientific News
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Pandemic E. coli Strain Cloaks its Stealth Strategies
Antibiotic resistance and weakened immunity only partially explain persistent, harmful infection.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!